2013

Nicox acquires Eupharmed

Wednesday, November 27, 2013

Nicox, an international pharmaceutical company focused on the ophthalmic market, has acquired Eupharmed, a privately-held Italian ophthalmic company, for $4.8 million in newly issued Nicox shares, plus milestones of up to $3.3 million. The acquisition provides Nicox with an established sales and marketing platform in Italy and a broad portfolio of eye care products. Eupharmed had sales of $4.9 million in 2012 and is expected to see full-year sales of approximately $5.3 million in 2013.

[Read More]

Joseph L. Herring, Neil M. Kurtz elected to Team Health Holdings board of directors

Tuesday, November 26, 2013

Team Health Holdings, a provider of outsourced physician staffing solutions for hospitals, has announced that Joseph L. Herring and Neil M. Kurtz, M.D., were elected to the company’s board of directors. As chairman of the board and CEO of Covance, Herring leads one of the largest public CROs in the world, managing $2.5 billion in revenue and 12,000 employees in 65 countries. As president and CEO of Golden Living, a privately-held skilled nursing, hospice, home healthcare and institutional pharmacy company with more than 300 locations nationwide, Kurtz leads the largest company of its kind in the industry, managing approximately $3 billion in revenue and 43,000 employees.

[Read More]

Boehringer Ingelheim planning two global trials of Pradaxa

Tuesday, November 26, 2013

Boehringer Ingelheim Pharmaceuticals plans to initiate two new global clinical trials of PRADAXA. One of the new trials, RE-DUAL PCI (Randomized Evaluation of Dual Therapy with Dabigatran v. Triple Therapy Strategy with Warfarin in Patients with NVAF that have undergone PCI with Stenting), is designed to evaluate the efficacy and safety of PRADAXA in patients with non-valvular atrial fibrillation (NVAF) who have undergone percutaneous coronary intervention (PCI), also known as angioplasty, with stent placement. The second of the new trials, RE-SPECT ESUS(TM) (Randomized Evaluation in Secondary stroke Prevention Comparing the Thrombin inhibitor dabigatran etexilate v. ASA in Embolic Stroke of Undetermined Source), is designed to evaluate the efficacy and safety of PRADAXA as a secondary stroke prevention therapy in patients who have suffered an embolic stroke of undetermined source (ESUS). Embolic strokes occur when a blood clot forms somewhere in the body and travels through the bloodstream to the brain.

[Read More]

Novocure initiates NovoTTF Therapy trial for brain metastases from NSCLC

Tuesday, November 26, 2013

Novocure, a privately-held Jersey Isle oncology company, has enrolled the first patients in the EF-21 Study, a prospective randomized clinical study of NovoTTF Therapy for patients with brain metastases from non-small cell lung carcinoma (NSCLC) cancer. NovoTTF Therapy is an anti-mitotic treatment delivered continuously throughout the day by the NovoTTF-100A System.

[Read More]